Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.750
-0.020 (-0.53%)
At close: Dec 5, 2025, 4:00 PM EST
3.790
+0.040 (1.07%)
After-hours: Dec 5, 2025, 5:52 PM EST
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$788,351
Market Cap
41.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LTRN News
- 2 days ago - Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Business Wire
- 15 days ago - Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript - Seeking Alpha
- 22 days ago - Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 4 weeks ago - Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET - Business Wire
- 5 weeks ago - Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - Business Wire
- 5 weeks ago - Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - Business Wire
- 6 weeks ago - Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - Business Wire